

# IHCP *bulletin*

INDIANA HEALTH COVERAGE PROGRAMS BT202129 APRIL 8, 2021

## DDRS waiver providers to provide COVID-19 vaccines to eligible FSW and CIH waiver members

The Indiana Health Coverage Programs (IHCP) has granted approval for coronavirus disease 2019 (COVID-19) vaccines to be administered by a qualified healthcare provider under the Division of Disability and Rehabilitative Services (DDRS) Bureau of Developmental Disabilities Services (BDDS) Family Supports Waiver (FSW) and Community Integration and Habilitation (CIH) Waiver.

Eligible enrolled providers for these waivers rendering services to CIH and FSW waiver members may begin billing the IHCP on or after April 8, 2021, retroactive to services performed on or after **January 1, 2021**. The eligible vaccine and administration codes are listed in Table 1. For FSW and CIH waiver providers to bill for these vaccine codes, **providers must append modifier U7** with the applicable procedure code for the service to be reimbursed.



Providers will have 180 days from the date of this publication to submit claims retroactive to January 1, 2021. Claims submitted beyond the 180-day filing limit from the date of service, must include a copy of this bulletin page along with the claim to bypass timely filling.

*Table 1 – COVID-19 vaccine and administration codes eligible for FSW and CIH waiver providers when billed with modifier U7, effective for dates of service on or after January 1, 2021, unless otherwise noted*

| Procedure code | Description   | Notes                                       |
|----------------|---|---|
| 0001A          | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose  | Pfizer vaccine administration, first dose   |
| 0002A          | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose | Pfizer vaccine administration, second dose  |
| 0011A          | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose                        | Moderna vaccine administration, first dose  |
| 0012A          | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose                       | Moderna vaccine administration, second dose |

*Table 1 – COVID-19 vaccine and administration codes eligible for FSW and CIH waiver providers when billed with modifier U7, effective for dates of service on or after January 1, 2021, unless otherwise noted (Continued)*

| Procedure code | Description  | Notes   |
|----------------|--|---|
| 0031A          | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage, single dose | Janssen vaccine administration, single dose Effective 2/27/2021 |
| 91300          | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use   | Pfizer vaccine  |
| 91301          | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use   | Moderna vaccine   |
| 91303          | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage, for intramuscular use  | Janssen vaccine Effective 2/27/2021                             |

Providers are reminded that the vaccine is available at no charge to providers at this time. Therefore, the IHCP will pay at zero until further notice.

**QUESTIONS?**

If you have questions about this publication, please contact Customer Assistance at 1-800-457-4584.

**TO PRINT**

A [printer-friendly version](#) of this publication, in black and white and without photos, is available for your convenience.

**COPIES OF THIS PUBLICATION**

If you need additional copies of this publication, please download them from the [Bulletins](#) page of the IHCP provider website at [in.gov/medicaid/providers](http://in.gov/medicaid/providers).

**SIGN UP FOR IHCP EMAIL NOTIFICATIONS**

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope or sign up from the [IHCP provider website](#) at [in.gov/medicaid/providers](http://in.gov/medicaid/providers).

